Legal Representation
Attorney
Eric Lamb
USPTO Deadlines
Application History
28 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 12, 2024 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jun 10, 2024 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Oct 28, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 26, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Oct 26, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Oct 26, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 2, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 2, 2023 | NOAC | E | CORRECTED NOA E-MAILED | Loading... |
| Jun 1, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| May 5, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jun 1, 2023 | DPCC | D | DIVISIONAL PROCESSING COMPLETE | Loading... |
| May 5, 2023 | DRRR | I | DIVISIONAL REQUEST RECEIVED | Loading... |
| May 30, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| May 5, 2023 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED | Loading... |
| May 5, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 8, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Sep 13, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 13, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 24, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 9, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 28, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jun 28, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jun 28, 2022 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jun 28, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jun 22, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 23, 2021 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Oct 22, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 22, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of cancer, infectious disease, metabolic disease, and central nervous system disease; chemico-pharmaceutical preparations for the treatment of cancer, infectious disease, metabolic disease, and central nervous system disease; drugs for medical purposes, namely, anticancer preparations; biological preparations for the treatment of cancer, infectious disease, metabolic disease, and central nervous system disease; chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of cancer, infectious disease, metabolic disease, and central nervous system disease; medicines for human purposes for the treatment of cancer, infectious disease, metabolic disease, and central nervous system disease; medicines for human purposes in the nature of bioconjugate preparations for the treatment of cancer, infectious disease, metabolic disease, and central nervous system disease; pharmaceutical preparations, substances and compositions, namely, antibody-drug conjugates in the nature of medical diagnostic reagents; pharmaceutical preparations, namely, drug conjugates consisting primarily of pharmaceutical preparations for the treatment of cancer, infectious disease, metabolic disease, and central nervous system disease
Additional Information
Design Mark
The mark consists of the stylized wordings "WUXI" over "XDC", partially inside an incomplete oval outline that intersects with another incomplete oval outline. Below these appears the wording "THE BIOCONJUGATION LEADER" in stylized font.
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"WUXI" OR "BIOCONJUGATION"